Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7447200 | 0.81 | CYP2A13 (0.70) | CYP2A13ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL18356563 | 0.79 | ALDH1A1 (0.71) | CYP2A13ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL12626359 | 0.79 | CCR5 (0.52) | CYP2A13ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL5675256 | 0.79 | ALDH1A1 (0.66) | CYP2A13ALDH1A1KDM4ELMNAATM | |
| SCHEMBL5675319 | 0.79 | SIGMAR1 (0.64) | CYP2A13ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL5469942 | 0.79 | KMT2A (0.64) | CYP2A13ALDH1A1KDM4ELMNAATM | |
| SCHEMBL8108285 | 0.79 | SIGMAR1 (0.64) | CYP2A13ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL12663678 | 0.79 | MPO (0.72) | ALDH1A1KDM4ETSHRFAAHMPO | |
| SCHEMBL6818375 | 0.78 | ALDH1A1 (0.69) | CYP2A13ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL29067014 | 0.77 | CCR5 (0.53) | CYP2A13ALDH1A1KDM4ETSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232068-B | Compound and preparation method and application thereof | 北京中医药大学 | 2023-09-08 | — | — | CN | disclosed |
| CN-102863376-B | N-substituent methyl-3,5-is two replaces benzal base-4-piperidone and Synthesis and applications | SHANGHAI NORMAL UNIVERSITY (CN) | 2015-12-16 | — | — | CN | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| EP-2475661-B1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2475661-B1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| CN-102863376-A | N-substituted methyl-3,5-disubstituted benzylidene base-4-piperidone and preparation method and application thereof | UNIV SHANGHAI | 2013-01-09 | — | — | CN | disclosed |
| EP-2475661-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| CN-1930145-B | Cycloalkanopyridine derivative | MSD CO LTD | 2011-06-15 | — | — | CN | disclosed |
| WO-2011029842-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029842-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| CN-1930145-A | Cycloalkanopyridine derivative | BANYU PHARMA CO LTD (JP) | 2007-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | CYP2A13 3456/4885ALDH1A1 2784/4885KDM4E 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.